P. H. van der Graaf

发表

Pharmacokinetic Modeling of Paracetamol Uptake and Clearance in Zebrafish Larvae: Expanding the Allometric Scale in Vertebrates with Five Orders of Magnitude

H. Spaink, T. Hankemeier, V. Kantae, 2016, Zebrafish.

Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo.

M. Danhof, P. H. van der Graaf, D. Jonker, 2005, Pharmacology & therapeutics.

Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges

C. Gaiteri, D. Bennett, H. Geerts, 2019, CPT: pharmacometrics & systems pharmacology.

Analysis of asymmetry of agonist concentration-effect curves.

P. H. van der Graaf, R. Schoemaker, 1999, Journal of pharmacological and toxicological methods.

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.

Steven W. Martin, P. H. van der Graaf, B. Agoram, 2007, Drug discovery today.

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.

Paul Morgan, J. Arrowsmith, P. H. van der Graaf, 2012, Drug discovery today.

The influence of drug distribution and drug‐target binding on target occupancy: The rate‐limiting step approximation

P. H. van der Graaf, G. Vauquelin, W. E. A. de Witte, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant.

M. Danhof, P. H. van der Graaf, W. E. A. de Witte, 2016, Trends in pharmacological sciences.

Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology

Neil Benson, Tomomi Matsuura, Piet H. van der Graaf, 2013, Interface Focus.

Model reduction in mathematical pharmacology

Thomas J. Snowden, Piet H van der Graaf, Thomas J Snowden, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Impact of protein binding on receptor occupancy: a two-compartment model.

Neil Benson, Piet H van der Graaf, Lambertus A Peletier, 2010, Journal of theoretical biology.

Analysis of alpha1-adrenoceptors in rabbit lower urinary tract and mesenteric artery.

P. H. van der Graaf, V. Deplanne, C. Duquenne, 1997, European journal of pharmacology.

[Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists.

P. H. van der Graaf, D. Nisato, W. Bax, 1995, European journal of pharmacology.

Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.

B. Fermini, P. H. van der Graaf, M. Holbrook, 2011, Journal of pharmacological and toxicological methods.

A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds

P. H. van der Graaf, J. Stevens, J. Burggraaf, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development

Neil Benson, Piet H. van der Graaf, N. Benson, 2011, Pharmaceutical Research.

Frequency‐Domain Response Analysis for Quantitative Systems Pharmacology Models

T. Post, P. H. van der Graaf, P. Schulthess, 2017, CPT: pharmacometrics & systems pharmacology.

Biomarkers and biomeasures: key enablers for pharmacokinetic-pharmacodynamic modeling in drug discovery and development.

P. H. van der Graaf, B. Agoram, 2012, Bioanalysis.

Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent.

N. Benson, P. H. van der Graaf, L. Mcfadyen, 2010, British journal of clinical pharmacology.

Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases

P. H. van der Graaf, P. Bloomingdale, C. Pichardo-Almarza, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm

Andy Z. X. Zhu, A. Rolfe, A. Kierzek, 2020, Clinical pharmacology and therapeutics.

Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients

M. Danhof, L. Heitman, P. H. van der Graaf, 2016, Expert opinion on drug discovery.

Mathematical Modelling of Alternative Pathway of Complement System

L. Peletier, M. Biedzka-Sarek, P. H. van der Graaf, 2020, Bulletin of Mathematical Biology.

Blood‐Based Biomarkers of Quinpirole Pharmacology: Cluster‐Based PK/PD and Metabolomics to Unravel the Underlying Dynamics in Rat Plasma and Brain

T. Hankemeier, P. H. van der Graaf, E. D. de Lange, 2019, CPT: pharmacometrics & systems pharmacology.

Children Are Not Small Adults, but Can We Treat Them As Such?

P. H. van der Graaf, C. Knibbe, E. Krekels, 2019, CPT: pharmacometrics & systems pharmacology.

Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1

P. Jasper, J. Tolsma, P. H. van der Graaf, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Are Regulators Talking to Each Other Across Borders?

P. H. van der Graaf, 2020, Clinical pharmacology and therapeutics.

Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder.

P. H. van der Graaf, K. Beaumont, A. Stobie, 2007, Bioorganic & medicinal chemistry.

Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing.

M. Danhof, P. H. van der Graaf, S. Visser, 2015, Journal of pharmacological and toxicological methods.

Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C.

P. H. van der Graaf, P. Chan, H. Jones, 2012, British journal of clinical pharmacology.

Neuroactive Steroids Differ in Potency but Not in Intrinsic Efficacy at the GABAA Receptor in Vivo

L. Peletier, M. Danhof, P. H. van der Graaf, 2002, Journal of Pharmacology and Experimental Therapeutics.

Characterisation of the 5-HT receptor potentiating neurotransmission in rabbit bladder.

P. H. van der Graaf, M. Barras, I. Angel, 1996, European journal of pharmacology.

Analysis of receptor inactivation experiments with the operational model of agonism yields correlated estimates of agonist affinity and efficacy.

P. H. van der Graaf, W. Stam, 1999, Journal of pharmacological and toxicological methods.

Use of mathematics to guide target selection in systems pharmacology; application to receptor tyrosine kinase (RTK) pathways

L. Peletier, N. Benson, P. H. van der Graaf, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

A novel cardiovascular systems model to quantify drugs effects on the inter‐relationship between contractility and other hemodynamic variables

Eric I. Rossman, P. H. van der Graaf, H. Taghvafard, 2022, CPT: pharmacometrics & systems pharmacology.

High-performance liquid chromatography of the neuroactive steroids alphaxalone and pregnanolone in plasma using dansyl hydrazine as fluorescent label: application to a pharmacokinetic-pharmacodynamic study in rats.

M. Danhof, P. H. van der Graaf, S. Visser, 2000, Journal of chromatography. B, Biomedical sciences and applications.

The rise of systems pharmacology in drug discovery and development.

N. Benson, P. H. van der Graaf, 2014, Future medicinal chemistry.

Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid.

M. Danhof, P. H. van der Graaf, S. Visser, 2016, British journal of clinical pharmacology.

Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats

L. Peletier, M. Danhof, P. H. van der Graaf, 2002, Journal of Pharmacology and Experimental Therapeutics.

Systems Pharmacology and Pharmacodynamics

P. H. van der Graaf, 2017, CPT: Pharmacometrics & Systems Pharmacology.

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®

P. H. van der Graaf, D. Shah, Xiaoying Chen, 2019, The AAPS Journal.

Model‐informed target identification and validation through combining quantitative systems pharmacology with network‐based analysis

V. Chelliah, P. H. van der Graaf, Piet H. van der Graaf, 2022, CPT: pharmacometrics & systems pharmacology.

A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant

H. Geerts, P. H. van der Graaf, R. Rose, 2022, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetic-Pharmacodynamic Analysis of the EEG Effect of Alfentanil in Rats Followingβ-Funaltrexamine-Induced μOpioid Receptor “Knockdown”In Vivo

M. Danhof, A. IJzerman, P. H. van der Graaf, 2000, Pharmaceutical Research.

Modulation of agonist responses at the A(1) adenosine receptor by an irreversible antagonist, receptor-G protein uncoupling and by the G protein activation state.

A. IJzerman, M. Beukers, P. H. van der Graaf, 2002, Biochemical pharmacology.

Current methods used to investigate G protein coupled receptor oligomerisation.

P. H. van der Graaf, C. Harrison, 2006, Journal of pharmacological and toxicological methods.

Mechanism-Based Modeling of Functional Adaptation Upon Chronic Treatment with Midazolam

M. Danhof, P. H. van der Graaf, R. Voskuyl, 2000, Pharmaceutical Research.

Mechanism-Based Modeling of Adaptive Changes in the Pharmacodynamics of Midazolam in the Kindling Model of Epilepsy

M. Danhof, P. H. van der Graaf, R. Voskuyl, 1999, Pharmaceutical Research.

On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentration-effect curves following irreversible receptor inactivation.

M. Danhof, P. H. van der Graaf, 1997, Journal of pharmacological and toxicological methods.

Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point.

J. Smith, A. Woodcock, P. H. van der Graaf, 2013, The Journal of allergy and clinical immunology.

Physiologically Based Modelling Framework for Prediction of Pulmonary Pharmacokinetics of Antimicrobial Target Site Concentrations

P. H. van der Graaf, J. V. van Hasselt, P. Välitalo, 2022, Clinical pharmacokinetics.

A mathematical analysis of rebound in a target-mediated drug disposition model: I.Without feedback

P. H. van der Graaf, B. Agoram, G. Derks, 2013, Journal of Mathematical Biology.

Induced Pluripotent Stem Cells: From the Bedside to the Bench, and Hopefully Back Again

P. H. van der Graaf, S. V. Van Driest, 2020, Clinical pharmacology and therapeutics.

A New Minimal-Stress Freely-Moving Rat Model for Preclinical Studies on Intranasal Administration of CNS Drugs

M. Danhof, P. H. van der Graaf, J. Stevens, 2009, Pharmaceutical Research.

A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis

P. H. van der Graaf, M. Moerland, J. V. van Hasselt, 2022, Journal of Pharmacokinetics and Pharmacodynamics.

Methods of Model Reduction for Large-Scale Biological Systems: A Survey of Current Methods and Trends

Thomas J. Snowden, P. H. van der Graaf, M. Tindall, 2017, Bulletin of mathematical biology.

Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.

P. H. van der Graaf, M. Tute, K. Beaumont, 2006, Journal of medicinal chemistry.

Cross-membrane signal transduction of receptor tyrosine kinases (RTKs): from systems biology to systems pharmacology

L. Peletier, N. Benson, P. H. van der Graaf, 2013, Journal of mathematical biology.

Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats

T. Hankemeier, P. H. van der Graaf, J. Elassaiss-Schaap, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Diversity, Equity, and Inclusion: Translating Clinical Pharmacology for All

K. Giacomini, K. Venkatakrishnan, P. H. van der Graaf, 2023, Clinical pharmacology and therapy.

Integration of Omics Data Sources to Inform Mechanistic Modeling of Immune‐Oncology Therapies: A Tutorial for Clinical Pharmacologists

Vijayalakshmi Chelliah, Piet H van der Graaf, Georgia Lazarou, 2020, Clinical pharmacology and therapeutics.

Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo

Neil J Attkins, Piet H van der Graaf, P. H. van der Graaf, 2011, British journal of pharmacology.

Diversity in Clinical Pharmacology Coming of Age.

P. H. van der Graaf, 2022, Clinical pharmacology and therapeutics.

Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches.

H. Spaink, P. H. van der Graaf, T. Ottenhoff, 2021, Trends in pharmacological sciences.

How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review

P. H. van der Graaf, F. Roelfsema, J. Stevens, 2018, Pituitary.

Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor.

M. Danhof, P. H. van der Graaf, E. Cox, 1998, The Journal of pharmacology and experimental therapeutics.

Benextramine acts as an irreversible noncompetitive antagonist of U46619-mediated contraction of the rat small mesenteric artery.

P. H. van der Graaf, P. Saxena, W. Stam, 1996, European journal of pharmacology.

A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: application to inhaled bronchodilators.

P. H. van der Graaf, B. Agoram, P. Milligan, 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Drug disposition in obesity: toward evidence-based dosing.

M. Danhof, P. H. van der Graaf, C. Knibbe, 2015, Annual review of pharmacology and toxicology.

Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling.

M Danhof, M. Danhof, P. H. van der Graaf, 1997, International journal of clinical pharmacology and therapeutics.

Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy

Thomas Hankemeier, T. Hankemeier, V. Kantae, 2016, Metabolomics.

Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples.

M. Danhof, P. H. van der Graaf, H. Niederländer, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments

D. Tibboel, M. Danhof, P. H. van der Graaf, 2018, CPT: pharmacometrics & systems pharmacology.

Systemic and Direct Nose-to-Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration

B. Ploeger, M. Danhof, P. H. van der Graaf, 2011, Drug Metabolism and Disposition.

Model‐Informed Drug Development: Connecting the Dots With a Totality of Evidence Mindset to Advance Therapeutics

K. Venkatakrishnan, P. H. van der Graaf, 2021, Clinical pharmacology and therapeutics.

Toward Project Optimus for Oncology Precision Medicine: Multi‐Dimensional Dose Optimization Enabled by Quantitative Clinical Pharmacology

K. Venkatakrishnan, P. H. van der Graaf, 2022, Clinical pharmacology and therapeutics.

Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan.

L. Peletier, M. Danhof, P. H. van der Graaf, 2002, European journal of pharmacology.

Design principles of collateral sensitivity-based dosing strategies

P. H. van der Graaf, D. Rozen, J. V. van Hasselt, 2021, Nature Communications.

Model informed quantification of the feed‐forward stimulation of growth hormone by growth hormone‐releasing hormone

P. H. van der Graaf, J. Stevens, J. Burggraaf, 2020, British journal of clinical pharmacology.

Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy

P. H. van der Graaf, R. Wallis, Krina Mehta, 2022, bioRxiv.

Mathematical Biology Models of Parkinson's Disease

Vijayalakshmi Chelliah, Piet H. van der Graaf, V. Chelliah, 2018, CPT: pharmacometrics & systems pharmacology.

Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling

P. H. van der Graaf, J. Stevens, J. Burggraaf, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer’s Disease

H. Geerts, P. H. van der Graaf, 2021, Journal of Alzheimer's disease reports.

Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics

A. Kierzek, P. H. van der Graaf, P. Padmanabhan, 2021, International Journal of Antimicrobial Agents.

Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats

L. Peletier, M. Danhof, P. H. van der Graaf, 2004, Journal of Pharmacology and Experimental Therapeutics.

Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction

P. H. van der Graaf, J. V. van Hasselt, W. Stam, 2018, British journal of pharmacology.

Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo.

M Danhof, M. Danhof, A. IJzerman, 1999, The Journal of pharmacology and experimental therapeutics.

Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat.

M Danhof, M. Danhof, P. H. van der Graaf, 1999, Journal of pharmaceutical sciences.

Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine.

T. Hankemeier, P. H. van der Graaf, C. Knibbe, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology

P. H. van der Graaf, A. Betts, 2020, Clinical pharmacology and therapeutics.

Analysis of α1L‐adrenoceptor pharmacology in rat small mesenteric artery

P. H. van der Graaf, P. Saxena, W. Stam, 1999 .

Mush Room for Improving Therapeutic Approaches in Psychiatry.

P. H. van der Graaf, 2023, Clinical pharmacology and therapeutics.

The alpha 1-adrenoceptor agonist, SDZ NVI-085, behaves as a potent, competitive antagonist of 5-hydroxytryptamine-induced contraction of rat aorta.

P. H. van der Graaf, P. Saxena, S. Apaydin, 1995, European journal of pharmacology.

Crowdsourced Asparagus Urinary Odor Population Kinetics

Lei Zhang, P. H. van der Graaf, B. Sadler, 2017, CPT: pharmacometrics & systems pharmacology.

Diversity in Clinical Pharmacology and Therapeutics.

P. H. van der Graaf, 2021, Clinical pharmacology and therapeutics.

The Pharmacological War Against and With Opioids.

P. H. van der Graaf, 2021, Clinical pharmacology and therapeutics.

The Changing Face of Oncology Research, Drug Development, and Clinical Practice: Toward Patient-Focused Precision Therapeutics.

K. Venkatakrishnan, P. H. van der Graaf, S. Holstein, 2020, Clinical pharmacology and therapeutics.

Clinical Pharmacology & Therapeutics 2030

Piet H van der Graaf, K. Giacomini, P. H. van der Graaf, 2020, Clinical pharmacology and therapeutics.

A mathematical analysis of rebound in a target-mediated drug disposition model: II. With feedback

P. H. van der Graaf, B. Agoram, G. Derks, 2014, Journal of mathematical biology.

Impact of plasma-protein binding on receptor occupancy: an analytical description.

L. Peletier, N. Benson, P. H. van der Graaf, 2009, Journal of theoretical biology.

Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models

L. Peletier, M. Danhof, V. Rottschäfer, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

In vitro and in silico analysis of the effects of D 2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations

M. Danhof, P. H. van der Graaf, S. Gul, 2018, British journal of pharmacology.

Correction to: Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models

Vivi Rottschäfer, Lambertus A. Peletier, Meindert Danhof, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.

Meindert Danhof, Piet H van der Graaf, B. Ploeger, 2009, Drug metabolism and pharmacokinetics.

Impact of post-hatching maturation on the pharmacokinetics of paracetamol in zebrafish larvae

T. Hankemeier, V. Kantae, E. H. Krekels, 2019, Scientific Reports.

Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors.

M Danhof, M. Danhof, A. IJzerman, 1997, The Journal of pharmacology and experimental therapeutics.

Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network

Alex Phipps, Paolo Vicini, James W. T. Yates, 2019, CPT: pharmacometrics & systems pharmacology.

MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key Challenges

Marc R Gastonguay, Daren Austin, Sandra A G Visser, 2020, Clinical pharmacology and therapeutics.

Functional characterisation of the pharmacological profile of the putative alpha1B-adrenoceptor antagonist, (+)-cyclazosin.

P. H. van der Graaf, P. Saxena, W. Stam, 1998, European journal of pharmacology.

Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery.

P. H. van der Graaf, P. Saxena, W. Stam, 1999, British Journal of Pharmacology.

Analysis of the activity of alpha 1-adrenoceptor antagonists in rat aorta.

J. Black, P. H. van der Graaf, N. Shankley, 1996, British Journal of Pharmacology.

A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia.

Meindert Danhof, Lambertus A Peletier, L. Peletier, 2002, The Journal of pharmacology and experimental therapeutics.

A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia.

P H van der Graaf, M Danhof, L. Peletier, 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

Synthesis and use of FSCPX, an irreversible adenosine A1 antagonist, as a 'receptor knock-down' tool.

A. IJzerman, M. Beukers, P. H. van der Graaf, 2001, Bioorganic & medicinal chemistry letters.

Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of D 2 receptor activation using multi‐biomarker pharmacokinetic/pharmacodynamic modelling

P. H. van der Graaf, Y. Wong, Robin Hartman, 2018, British journal of pharmacology.

Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics

T. Hankemeier, P. H. van der Graaf, W. Brink, 2018, Expert opinion on drug discovery.

Dose-Dependent EEG Effects of Zolpidem Provide Evidence for GABAA Receptor Subtype Selectivity in Vivo

L. Peletier, M. Danhof, P. H. van der Graaf, 2003, Journal of Pharmacology and Experimental Therapeutics.

Biomarker‐Guided Individualization of Antibiotic Therapy

D. D. de Lange, P. H. van der Graaf, J. V. van Hasselt, 2021, Clinical pharmacology and therapeutics.

Optimising in vivo pharmacology studies--Practical PKPD considerations.

Johan Gabrielsson, A Richard Green, Piet H Van der Graaf, 2010, Journal of pharmacological and toxicological methods.

Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development.

Johan Gabrielsson, P. H. van der Graaf, J. Gabrielsson, 2009, Future medicinal chemistry.

Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats.

L. Peletier, M. Danhof, P. H. van der Graaf, 2002, The Journal of pharmacology and experimental therapeutics.

Towards personalized treatment of pain using a quantitative systems pharmacology approach.

T. Hankemeier, D. Tibboel, M. van Dijk, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Learn–confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform

A. Kierzek, M. Swat, P. H. van der Graaf, 2022, CPT: pharmacometrics & systems pharmacology.

Immunogenicity in Clinical Practice and Drug Development: When is it Significant?

Craig J. Thalhauser, Yow-Ming C Wang, A. Kierzek, 2019, Clinical and translational science.

Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development

H. Spaink, Rob C. van Wijk, P. H. van der Graaf, 2020, Clinical and translational science.

Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalogram Effects of GABAA Receptor Modulators: In Vitro-in Vivo Correlations

M Danhof, L. Peletier, M. Danhof, 2003, Journal of Pharmacology and Experimental Therapeutics.

Optimization of Cancer Treatment in the Frequency Domain

James W. T. Yates, Pascal Schulthess, Vivi Rottschäfer, 2019, The AAPS Journal.

Application of a systems pharmacology model for translational prediction of hERG‐mediated QTc prolongation

M. Danhof, P. H. van der Graaf, S. Visser, 2016, Pharmacology research & perspectives.

Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach

P. H. van der Graaf, Jan Berkhout, A. Keunecke, 2018, mAbs.

A cross‐species translational pharmacokinetic‐pharmacodynamic evaluation of core body temperature reduction by the TRPM8 blocker PF‐05105679

P. H. van der Graaf, K. Beaumont, W. Winchester, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

A Quantitative Systems Pharmacology Perspective on the Importance of Parameter Identifiability

Gary R. Mirams, P. Pathmanathan, S. Niederer, 2022, Bulletin of mathematical biology.

FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective

Justin C. Earp, Christina M. Friedrich, K. Gadkar, 2021, The AAPS Journal.

Salvaging CNS Clinical Trials Halted Due to COVID‐19

H. Geerts, P. H. van der Graaf, 2020, CPT: Pharmacometrics & Systems Pharmacology.

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®

P. H. van der Graaf, D. Shah, Xiaoying Chen, 2019, The AAPS Journal.

Have many estimates of efficacy and affinity been misled? Revisiting the operational model of agonism.

J. Giraldo, P. H. van der Graaf, D. Roche, 2016, Drug discovery today.

Correction to: Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models

L. Peletier, M. Danhof, V. Rottschäfer, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Outside‐In Systems Pharmacology Combines Innovative Computational Methods With High‐Throughput Whole Vertebrate Studies

James W T Yates, Pascal Schulthess, Rob C van Wijk, 2018, CPT: pharmacometrics & systems pharmacology.

Modelling inflammatory biomarker dynamics in a human lipopolysaccharide (LPS) challenge study using delay differential equations

P. H. van der Graaf, M. Moerland, Tingjie Guo, 2022, British journal of clinical pharmacology.

Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry.

Michael Rowley, Johan Ulander, Johan Gabrielsson, 2011, Current topics in medicinal chemistry.

Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy

T. Hankemeier, V. Kantae, A. Harms, 2016, Metabolomics.

Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling

P. H. van der Graaf, Krina Mehta, Tingjie Guo, 2023, Clinical Pharmacokinetics.

Mechanistic and Quantitative Understanding of Pharmacokinetics in Zebrafish Larvae through Nanoscale Blood Sampling and Metabolite Modeling of Paracetamol

H. Spaink, T. Hankemeier, V. Kantae, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Pharmacokinetic-Pharmacodynamic Modeling of Alpha Interferon Response Induced by a Toll-Like 7 Receptor Agonist in Mice

N. Benson, P. H. van der Graaf, J. de Jongh, 2009, Antimicrobial Agents and Chemotherapy.

A mathematical model of the human menstrual cycle for the administration of GnRH analogues.

Peter Deuflhard, Susanna Röblitz, David-Olivier Azulay, 2013, Journal of theoretical biology.

Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency.

Gianne Derks, Philip J Aston, Piet H van der Graaf, 2011, Journal of theoretical biology.

Methods of Model Reduction for Large-Scale Biological Systems: A Survey of Current Methods and Trends

Thomas J. Snowden, Piet H van der Graaf, Thomas J Snowden, 2017, Bulletin of Mathematical Biology.

Immunogenicity in Clinical Practice and Drug Development: When is it Significant?

Craig J. Thalhauser, Yow-Ming C Wang, A. Kierzek, 2019, Clinical and translational science.

A modeling informed quantitative approach to salvage clinical trials interrupted due to COVID‐19

Hugo Geerts, Piet van der Graaf, H. Geerts, 2020, Alzheimer's & dementia.

Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models

L. Peletier, M. Danhof, V. Rottschäfer, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C.

P. H. van der Graaf, P. Chan, H. Jones, 2012, British journal of clinical pharmacology.

Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients

M. Danhof, L. Heitman, P. H. van der Graaf, 2016, Expert opinion on drug discovery.

Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network

Alex Phipps, Lourdes Cucurull-Sanchez, Jon Timmis, 2019, CPT: pharmacometrics & systems pharmacology.

Estimation of binding rate constants using a simultaneous mixed‐effects method: application to monoamine transporter reuptake inhibitor reboxetine

B. Ploeger, N. Benson, R. Butt, 2010, British journal of pharmacology.

Prediction of long-term treatment outcome in HCV following 24 day PEG-IFN alpha-2b therapy using population pharmacokinetic-pharmacodynamic mixture modeling and classification analysis.

O. Demin, N. Benson, P. H. van der Graaf, 2015, Journal of theoretical biology.

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease

H. Geerts, P. H. van der Graaf, E. Schuck, 2023, CPT: pharmacometrics & systems pharmacology.

Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid

M. Danhof, P. H. van der Graaf, S. Visser, 2015, Pharmaceutical Research.